PMID: 11317691Apr 25, 2001Paper

Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003

International Journal of Colorectal Disease
Stefan SchreiberBMBF Competence Network "Inflammatory Bowel disease"

Abstract

The introduction of novel anti-tumor necrosis factor (TNF) agents has not only led to impressive new therapeutic opportunities but also resulted in uncertainty regarding their optimal use and possible side effects. Guidelines are presented here for the use of anti-TNF agents in gastrointestinal disorders. Experts were chosen from different European countries by an algorithm to avoid bias. An expert consensus on guidelines was established using a two-stage procedure of systematic Medline and abstract search for evidence and a qualifying meeting to derive recommendations. Detailed guidelines were developed for the use and the future clinical development of anti-TNF agents in inflammatory bowel disease. Grading of available evidence and grading of recommendations were performed according to AHCPR guidelines. At present infliximab is the only registered agent for Crohn's disease. Infliximab should be always used at a dose of 5 mg/kg. The guidelines define the indications both in refractory and in fistulating disease for the readministration and before surgery. Guidelines for safety and for concomitant treatments are given. Prospects, potential clinical use, and future directions for the clinical development of other anti-TNF agents...Continue Reading

Citations

Sep 21, 2001·Alimentary Pharmacology & Therapeutics·I D ArnottS Ghosh
Sep 28, 2004·Langenbeck's Archives of Surgery·Britta Siegmund, Martin Zeitz
Jun 14, 2005·International Journal of Colorectal Disease·Dario SorrentinoEster Zearo
Oct 29, 2013·Expert Review of Gastroenterology & Hepatology·Dario SorrentinoJohan Van den Bogaerde
Nov 8, 2002·International Journal of Colorectal Disease·S Schreiber
Mar 27, 2003·Journal of Pediatric Gastroenterology and Nutrition·Arie LevineJames Markowitz
Sep 1, 2004·International Journal of Colorectal Disease·Astrid KonradFrank Seibold
Jan 23, 2003·The Annals of Otology, Rhinology, and Laryngology·Francesco OttavianiGabriele Bianchi Porro
Dec 1, 2005·Scandinavian Journal of Gastroenterology·Takayuki MatsumotoToshifumi Hibi
Feb 14, 2008·Internal and Emergency Medicine·Salvatore CorraoGiuseppe Licata
Jan 28, 2005·Inflammatory Bowel Diseases·Yago González-LamaPedro Escartin
Jan 18, 2007·Clinical Rheumatology·Salvatore CorraoGiuseppe Licata
Dec 23, 2011·Expert Opinion on Biological Therapy·Mauro ViganòMassimo Colombo
Dec 18, 2001·Experimental Biology and Medicine·J L Wallace, L Ma

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.